

Combinations of antibiotics effective against Extensively- and Pandrug Resistant *Acinetobacter* *baumannii* patient isolates

Justin Halim, Rachel A. Carr, Rebecca Fliorent, Keertana Jonnalagadda, Maftuna Kurbonnazarova,
Muskanjot Kaur, Ian Millstein, and Valerie J. Carabetta¹

Contents

Table S2: List of combinations screened by disc diffusion assay.....	2
Figure S1: Representative checkerboard assay with cefepime and tobramycin.....	3
Figure S2: Representative checkerboard assay with amikacin and eravacycline.....	4
Figure S3: Representative checkerboard assay with eravacycline and rifampin.	5
Figure S4: Representative checkerboard assay with omadacycline and levofloxacin.	6

Table S2: List of combinations screened by disc diffusion assay.

Antibiotic Combination	Synergy Observed
Amikacin x Eravacycline	Yes
Amikacin x Cefepime	Yes
Amikacin x Meropenem	No
Amikacin x Levofloxacin	Yes
Amikacin x Amp/Sul	No
Amikacin x TMP/SMX	No
Amikacin x Rifampin	No
Amikacin x Doxycycline	No
Eravacycline x Cefepime	No
Eravacycline x Meropenem	No
Eravacycline x Levofloxacin	Yes
Eravacycline x Amp/Sul	Yes
Eravacycline x TMP/SMX	No
Eravacycline x Rifampin	Yes
Omadacycline x Cefepime	No
Omadacycline x Meropenem	No
Omadacycline x Levofloxacin	Yes
Omadacycline x Amp/Sul	Yes
Omadacycline x TMP/SMX	No
Omadacycline x Rifampin	Yes
Cefepime x Meropenem	No
Cefepime x Levofloxacin	Yes
Cefepime x Amp/Sul	Yes
Cefepime x TMP/SMX	No
Cefepime x Rifampin	Yes
Cefepime x Doxycycline	No
Meropenem x Levofloxacin	No
Meropenem x Amp/Sul	No
Meropenem x TMP/SMX	No
Meropenem x Rifampin	No
Meropenem x Doxycycline	No
Levofloxacin x Amp/Sul	Yes
Levofloxacin x TMP/SMX	No
Levofloxacin x Rifampin	No
Levofloxacin x Doxycycline	No
Amp/Sul x TMP/SMX	No
Amp/Sul x Rifampin	No
Amp/Sul x Doxycycline	No
TMP/SMX x Rifampin	No
TMP/SMX x Doxycycline	No




Figure S1: Representative checkerboard assay with cefepime and tobramycin against strain M13. Top: OD₆₀₀ measurements following 16 hours of static growth at 37°C. The MIC values for each drug alone are highlighted in gray. The pink boxes indicate wells in which no bacterial growth occurred (OD₆₀₀ < 0.1), and green boxes indicate wells in which bacterial growth did occur. The box in the bottom right corner contains no drug and serves as a growth control. Bottom: Fractional inhibitory concentrations (FICs) were calculated for each drug (concentration/MIC) and added together for all wells where no growth was observed. The yellow boxes indicate additive interactions (FICI between 0.5-1.0), and blue boxes indicate synergistic interactions (FICI ≤ 0.5).




Figure S2: Representative checkerboard assay with amikacin and eravacycline against strain M2. Top: OD₆₀₀ measurements following 16 hours of static growth at 37°C. The MIC values for each drug alone are highlighted in gray. The pink boxes indicate wells in which no bacterial growth occurred (OD₆₀₀ < 0.1), and green boxes indicate wells in which bacterial growth did occur. The box in the bottom right corner contains no drug and serves as a growth control. Bottom: Fractional inhibitory concentrations (FICs) were calculated for each drug (concentration/MIC) and added together for all wells where no growth was observed. The yellow boxes indicate additive interactions (FICI between 0.5-1.0).




Figure S3: Representative checkerboard assay with eravacycline and rifampin against strain M22. Top: OD₆₀₀ measurements following 16 hours of static growth at 37°C. The MIC values for each drug alone are highlighted in gray. The pink boxes indicate wells in which no bacterial growth occurred (OD₆₀₀ < 0.1), and green boxes indicate wells in which bacterial growth did occur. The box in the bottom right corner contains no drug and serves as a growth control. Bottom: Fractional inhibitory concentrations (FICs) were calculated for each drug (concentration/MIC) and added together for all wells where no growth was observed. The yellow boxes indicate additive interactions (FICI between 0.5-1.0), and blue boxes indicate synergistic interactions (FICI ≤ 0.5).




Figure S4: Representative checkerboard assay with omadacycline and levofloxacin against strain M17. Top: OD₆₀₀ measurements following 16 hours of static growth at 37°C. The MIC values for each drug alone are highlighted in gray. The pink boxes indicate wells in which no bacterial growth occurred (OD₆₀₀ < 0.1), and green boxes indicate wells in which bacterial growth did occur. The box in the bottom right corner contains no drug and serves as a growth control. Bottom: Fractional inhibitory concentrations (FICs) were calculated for each drug (concentration/MIC) and added together for all wells where no growth was observed. The yellow boxes indicate additive interactions (FICI between 0.5-1.0), and blue boxes indicate synergistic interactions (FICI ≤ 0.5).